In the US pharmaceutical industry, there were 31 private equity deals announced in Q4 2023, worth a total value of $700.5m, according to GlobalData’s Deals Database. The $375m management buy-in (mbi) ZimVie by H.I.G. Capital was the industry’s largest disclosed deal. In value terms, private equity deal activity in the US decreased by 84% in Q4 2023 compared with the previous quarter’s total of $4.3bn and fell by 63% as compared to Q4 2022. Related deal volume increased by 24% in Q4 2023 versus the previous quarter and was 39% lower than in Q4 2022.
Read the full article: Q4 2023 Update: Private Equity Deals in the Pharmaceutical Industry in the US //
Source: https://www.pharmaceutical-technology.com/data-insights/theus-privateequity-activity-pharmaceutical-industry